01099 SINOPHARM
- 21.550
- -0.200-0.92%
SINOPHARM News
國藥控股：年度報告2023
國藥控股：公告 國藥股份截至2024年3月31日止第一季度之 主要未經審核會計數據和財務指標
Sinopharm Holdings (01099): Sinopharm (000028.SZ) net profit of about 389 million yuan in the first quarter increased 7.33% year-on-year
Sinopharm Holdings (01099) announced Sinopharm's (000028.SZ) results for the first quarter of 2024, operating...
國藥控股：公告 國藥一致截至2024年3月31日止第一季度之 主要未經審核會計數據和財務指標
Hong Kong Stock Concept Tracking | The 2024 trend of mergers and acquisitions of pharmaceutical distribution companies is expected to further accelerate leading state-owned enterprises to attract attention (with concept stocks)
The trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to accelerate further, and the concentration of leaders may further increase
SDIC Securities: The industry is heavily state-owned capital, and the trend of mergers and acquisitions of pharmaceutical distribution companies is expected to accelerate further in 24 years
The new round of state-owned enterprise reform also emphasizes specialized integration in the medical and health sector. The pharmaceutical distribution industry is heavily state-owned and driven by superposition policies. At the time point of 2024, the trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to further accelerate.
[Broker Focus] CMB International expects China's pharmaceutical industry to return to healthy growth this year
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has fallen 22.7%, outperforming the MSCI China Index by 23.3%. Looking ahead to 2024, China's pharmaceutical industry is expected to return to healthy growth as industry regulation is normalized and the impact of the COVID-19 base gradually subsides. The bank continues to be optimistic about BeiGene (06160), Cinda Biotech (01801), Columbotai (06990), Giant Biotech (02367), Gushengtang (02273), and Mindray Healthcare (300760). Additionally, it is recommended to focus on high-dividend stocks with steady performance, such as Regal Healthcare
Sinopharm Holdings (01099.HK) plans to hold a board meeting on April 26 to approve quarterly results
Gelonghui, April 16, 丨 Sinopharm Holdings (01099.HK) announced that the board of directors will hold a board meeting on April 26, 2024 (Friday) to consider and approve (including) the unaudited quarterly results of the company and its subsidiaries for the three months ended March 31, 2024.
國藥控股：董事會會議通告
Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might
Sinopharm Holdings received 997,600 additional shares from FMR LLC at a price of approximately HK$20.49 per share
According to the latest data from the Hong Kong Stock Exchange, on April 2, FMR LLC increased its holdings of Sinopharm Holdings (01099) by 997,600 shares, at a price of HK$20.4938 per share, for a total amount of about HK$204.44,600. After the increase in holdings, the latest number of shares held was about 162 million shares, and the latest shareholding ratio was 12.04%.
Sinopharm Holdings (01099.HK) gains 997,600 shares from FMR LLC
Gelonghui, April 9 | According to the latest equity disclosure data on the Stock Exchange, on April 2, 2024, Sinopharm Holdings (01099.HK) received FMR LLC an increase of 997,600 shares at an average price of HK$20.4938 per share on the market, involving approximately HK$20.445 million. After the increase in holdings, FMR LLC's latest shareholding was 161,576,874 shares, and the shareholding ratio increased from 11.97% to 12.04%.
Sinopharm Holdings (01099): Sinopharm (000028.SZ)'s 2023 net profit of 1,599 billion yuan increased 7.57% year-on-year
Sinopharm Holdings (01099) issued an announcement. Sinopharm Group, a subsidiary of the company, is united Pharmaceutical Co., Ltd. (Sinopharm 1...
SINOPHARM: ANNOUNCEMENT PRINCIPAL AUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE YEAR ENDED 31 DECEMBER 2023
[Broker Focus] No. 1 Shanghai maintains Sinopharm Holdings (01099) purchase rating, indicating that its pharmaceutical business and retail business will continue to develop steadily
Jinwu Financial News | According to the First Shanghai Development Research Report, Sinopharm Holdings (01099) achieved revenue of 596.57 billion yuan in 2023, an increase of 8.1% over the previous year. Profit for the period increased 4.6% year on year to 15.01 billion yuan, while profit attributable to shareholders during the period increased 6.2% year on year to 9.05 billion yuan. The dividend is $0.87 per share, and the payout ratio is 30%. According to the bank, as China's aging process accelerates, the company's pharmaceutical business and retail business will continue to develop steadily. The company hopes to maintain a steady development rate of 2-3 percentage points higher than the industry's growth rate for a long time, using pharmaceutical marketing, supply chain services and devices
Changes in Hong Kong stocks | Sinopharm Holdings (01099) rose nearly 4% in the afternoon, net profit for the whole year increased 6.2%, and Daiwa said profit for the fourth quarter exceeded expectations
The Zhitong Finance App learned that Sinopharm Holdings (01099) rose nearly 4% in the afternoon. As of press release, it had risen 3.71% to HK$20.7, with a turnover of HK$37.7066 million. According to the news, Sinopharm Holdings announced annual results up to the end of December last year, with a turnover of 596.57 billion yuan, up 8% year on year; net profit of 9.54 billion yuan, up 6.2% year on year; and profit of 2.9 yuan per share. The final interest rate was 87 points per share, compared to 82 points for the same period last year. Citi said that the company's performance was generally in line with the bank's and market expectations. Management indicated that the business continues to recover from anti-corruption, and drug sales revenue is expected to increase this year
Lyon: Reiterates Sinopharm Holdings' “Buy” Rating Target Price Reduced to HK$27
Lyon released a research report saying that Sinopharm Holdings (01099)'s performance in the final quarter of last year gradually improved, as the impact of fighting corruption in mainland medicine gradually subsided until the end of last year. At the end of last year, the company's revenue increased 3.9% quarterly, and net profit increased 48.5% quarterly to RMB 3 billion. The company focuses on profit expansion. It is expected that its emerging medical device manufacturing business will drive profit expansion and reaffirm the “buy” rating. The target price was slightly lowered from HK$27.1 to HK$27.
[Hong Kong Stock Connect] Sinopharm Holdings (01099) rebounded the market and rose nearly 3%, and Yamato indicated that its profit performance in the previous quarter exceeded expectations
Jinwu Financial News | Sinopharm Holdings (01099) bucked the market. As of press release, it reported HK$20.55, up 2.96%, with a turnover of HK$32.870,400. According to a research report published by Yamato, Sinopharm's profit performance in the last quarter was mainly driven by higher gross margin than expected, as well as non-operating income and lower financial expenses. Revenue for the last quarter increased by 3.4% year-on-year, which was the same year over year in the third quarter of last year, reflecting the return of the company's revenue to a growth trajectory. According to the bank, the pressure on the Group's gross margin in the fourth quarter of last year seems to have decreased compared to the first three quarters of last year. It is expected that gross margin will continue to improve from 2023 to 2026, and
Lyon: Reiterates Sinopharm Holdings' (01099) “Buy” Rating Target Price Reduced to HK$27
The Zhitong Finance App learned that Lyon released a research report saying that Sinopharm Holdings (01099)'s performance in the final quarter of last year gradually improved, as the impact of mainland pharmaceutical corruption gradually subsided until the end of last year. At the end of last year, the company's revenue increased 3.9% quarterly, and net profit increased 48.5% quarterly to RMB 3 billion. The company focuses on profit expansion. It is expected that its emerging medical device manufacturing business will drive profit expansion and reaffirm the “buy” rating. The target price was slightly lowered from HK$27.1 to HK$27.
Earnings Update: Sinopharm Group Co. Ltd. (HKG:1099) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Last week, you might have seen that Sinopharm Group Co. Ltd. (HKG:1099) released its annual result to the market. The early response was not positive, with shares down 2.2% to HK$19.96 in the past wee
Analysis
Price Target
No Data
